M55 Stock Chart & Stats
€3.18
-€0.16(-4.79%)
At close: 4:00 PM EDT
€3.18
-€0.16(-4.79%)
Day’s Range― - ―
52-Week Range€1.14 - €4.22
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€203.38M
Enterprise Value€134.36
Total Cash (Recent Filing)€154.23M
Total Debt (Recent Filing)€36.51M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding63,563,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.83
Price to Sales (P/S)0.68
P/FCF Ratio-1.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.57Price Target Upside75.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.08
Revenue Forecast (FY)€119.81M
Bulls Say, Bears Say
Bulls Say
Asset-light Shift And Supply AgreementSelling GMP manufacturing and outsourcing production creates an asset-light model that reduces capital intensity and ongoing facility costs. The supply agreement with Bora secures manufacturing capacity for clinical/commercial needs, freeing cash and management focus to advance R&D and pipeline programs over the medium term.
Expanded Non-dilutive Royalty FinancingThe expanded royalty purchase provides meaningful non-dilutive liquidity to fund clinical development without issuing equity. By preserving milestone upside and structuring capped royalties, MacroGenics gains near-term financial flexibility while maintaining long-term commercial economics that support ongoing pipeline investment.
Solid Revenue Base With Strong Gross MarginsSizable collaboration and product-related revenue combined with high gross margins indicate the core business generates meaningful gross profit. This structural revenue quality supports funding for R&D and partnerships, and provides a durable operating lever if management controls operating expenses or achieves milestone monetizations.
Bears Say
High Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flow demonstrate the company consumes significant cash to fund operations and trials. Over the next several quarters this structural burn necessitates recurring financing or asset monetization to sustain clinical programs, increasing dilution or refinancing risk if pipeline progress stalls.
Thin Equity Base And Elevated LeverageA thin equity base combined with higher debt-to-equity reduces financial flexibility and heightens vulnerability to adverse trial or market events. For a development-stage biotech reliant on external funding, this structural leverage increases refinancing pressure and could force dilutive financings or asset sales under stress.
Persistent Operating Losses And Negative Net MarginsSustained large operating losses reflect a cost structure outpacing revenues, typical for clinical-stage biotechs but problematic if development timelines extend. Without pathway to profitable operations or outsized milestone receipts, continued losses materially raise the probability of additional financing and constrain long-term shareholder value creation.
MacroGenics News
M55 FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was €1.14 and its highest was €4.22 in the past 12 months.
What is MacroGenics’s market cap?
MacroGenics’s market cap is €203.38M.
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Aug 11, 2026 which is in 8 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on May 13, 2026. The company reported -€0.503 earnings per share for the quarter, missing the consensus estimate of -€0.498 by -€0.005.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -0.07.
How many shares outstanding does MacroGenics have?
MacroGenics has 63,563,120 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of -€0.503 in its last earnings report, missing expectations of -€0.498. Following the earnings report the stock price went up 8.511%.
Which hedge fund is a major shareholder of MacroGenics?
Currently, no hedge funds are holding shares in DE:M55
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.57 (75.07% Upside)
€5.57 (75.07% Upside)
Blogger Sentiment
Neutral
DE:M55 Sentiment 67%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
MacroGenics
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
M55 Stock 12 Month Forecast
Average Price Target
€5.57
▲(75.07% Upside)